Absolute Event Rate: 934% vs 383%
p-value: p=<0.001
The development of a human TREK-1/HEK cell line provides a highly efficient in vitro screening tool for identifying novel modulators of TREK-1 channels for neurological diseases.
Enables TREK-1 modulator screening in vitro; leaves open translation to therapies for pain or depression.
TREK-1 potassium channels are involved in a number of physiopathological processes such as neuroprotection, pain and depression. Molecules able to open or to block these channels can be clinically important. Having a cell model for screening such molecules is of particular interest. Here, we describe the development of the first available cell line that constituvely expresses the TREK-1 channel. The TREK-1 channel expressed by the h-TREK-1/HEK cell line has conserved all its modulation properties. It is opened by stretch, pH, polyunsaturated fatty acids and by the neuroprotective molecule, riluzole and it is blocked by spadin or fluoxetine. We also demonstrate that the h-TREK-1/HEK cell line is protected against ischemia by using the oxygen-glucose deprivation model.
No takes yet. Share an insight, caveat, or question.
Maati et al. (2011) studied Neurological diseases (in vitro). h-TREK-1 expression vs. Native HEK cells was evaluated on Cell survival after oxygen-glucose deprivation (p=<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: